Terms: = Head and neck cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Clinical Outcome
16 results:
1. clinical outcome and prognostic factors in adenoid cystic carcinoma of the external auditory canal: proposal for a refined T-stage classification system.
Lee JY; Cho YS
Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3625-3633. PubMed ID: 36781438
[TBL] [Abstract] [Full Text] [Related]
2. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
[TBL] [Abstract] [Full Text] [Related]
3. Glucocorticoid receptor and serum- and glucocorticoid-induced kinase-1 in esophageal adenocarcinoma and adjacent Barrett's esophagus.
Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
Pathol Int; 2020 Jun; 70(6):355-363. PubMed ID: 32173971
[TBL] [Abstract] [Full Text] [Related]
4. APE1 Upregulates MMP-14 via Redox-Sensitive ARF6-Mediated Recycling to Promote Cell Invasion of Esophageal Adenocarcinoma.
Lu H; Bhat AA; Peng D; Chen Z; Zhu S; Hong J; Maacha S; Yan J; Robbins DJ; Washington MK; Belkhiri A; El-Rifai W
Cancer Res; 2019 Sep; 79(17):4426-4438. PubMed ID: 31308045
[TBL] [Abstract] [Full Text] [Related]
5. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract] [Full Text] [Related]
6. High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.
El Gammal AT; Melling N; Reeh M; Gebauer F; Mann O; Perez D; Bockhorn M; Bachmann K; Izbicki JR; Grupp K
Exp Mol Pathol; 2019 Apr; 107():51-56. PubMed ID: 30707896
[TBL] [Abstract] [Full Text] [Related]
7. FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas.
Grupp K; Uzunoglu FG; Melling N; Hofmann B; El Gammal AT; Grotelüschen R; Heumann A; Bellon E; Reeh M; Wolters-Eisfeld G; Ghabdan T; Nentwich M; Bachmann K; Bockhorn M; Bogoevski D; Izbicki JR; Kutup A
Sci Rep; 2018 Nov; 8(1):17370. PubMed ID: 30478420
[TBL] [Abstract] [Full Text] [Related]
8. AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking.
Maacha S; Hong J; von Lersner A; Zijlstra A; Belkhiri A
Neoplasia; 2018 Oct; 20(10):1008-1022. PubMed ID: 30189359
[TBL] [Abstract] [Full Text] [Related]
9. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract] [Full Text] [Related]
10. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
11. C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis.
Ren JL; Wu HF; Wang WJ; Hu GM; Gu B; Zhang M; Wang YX
Panminerva Med; 2017 Mar; 59(1):97-106. PubMed ID: 27636117
[TBL] [Abstract] [Full Text] [Related]
12. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.
Davison JM; Yee M; Krill-Burger JM; Lyons-Weiler MA; Kelly LA; Sciulli CM; Nason KS; Luketich JD; Michalopoulos GK; LaFramboise WA
PLoS One; 2014; 9(1):e79079. PubMed ID: 24454681
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.
Malhotra U; Zaidi AH; Kosovec JE; Kasi PM; Komatsu Y; Rotoloni CL; Davison JM; R C; Irvin ; Hoppo T; Nason KS; Kelly LA; Gibson MK; Jobe BA
PLoS One; 2013; 8(11):e78343. PubMed ID: 24223792
[TBL] [Abstract] [Full Text] [Related]
14. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract] [Full Text] [Related]
15. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.
Boonstra JJ; van Marion R; Tilanus HW; Dinjens WN
J Gastrointest Surg; 2011 Jan; 15(1):48-56. PubMed ID: 20922573
[TBL] [Abstract] [Full Text] [Related]
16. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
[TBL] [Abstract] [Full Text] [Related]
